Ibandronate: A review of its use in the management of postmenopausal osteoporosis

Drugs

Volumn 68, Issue 18, 2008, Pages 2683-2707

  Frampton, James E ^a,b   Perry, Caroline M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug evaluations; Ibandronic acid, general; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGITIS; FATIGUE; FLU LIKE SYNDROME; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; OSTEOPENIA; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RASH; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 57749185251     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868180-00011     Document Type: Review

References (135)

1. Reginster J-Y, Neuprez A, Bruyère O. Ibandronate in profile: drug characteristics and clinical profile. Expert Opin Drug Metab Toxicol 2008; 4 (7): 941-51
2. Roche Products Limited, Welwyn Garden City, UK. Bonviva 150mg film-coated tablets. Summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2008 Sep 11]
3. Roche Laboratories Inc., Nutley (NJ). Boniva® (ibandronate sodium) tablets. Prescribing information [online]. Available from URL: http://www.boniva.com [Accessed 2008 May 15]
4. Dando TM, Noble S. Once-monthly ibandronate. Treat Endocrinol 2005; 4 (6): 381-7
5. Pyon EY. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clin Ther 2006 Apr; 28 (4): 475-90
6. Roche Laboratories Inc., Nutley (NJ). Boniva® (ibandronate sodium) injection. Prescribing information [online]. Available from URL: http://www.boniva.com [Accessed 2008 May 15]
7. Roche Products Limited, Welwyn Garden City, UK. Bonviva 3 mg/3ml solution for injection in pre-filled syringe. Summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2008 May 15]
8. Croom KF, Scott LJ. Intravenous ibandronate: in the treatment of osteoporosis. Drugs 2006; 66 (12): 1593-601
9. Muller R, Recker RR. Bisphosphonate action on bone structure and strength: preclinical and clinical evidence for ibandronate. Bone 2007; 41 (5 Suppl. 1): S16-23
10. Bauss F, Dempster DW. Effects of ibandronate on bone quality: preclinical studies. Bone 2007 Feb; 40 (2): 265-73
11. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004 Jun; 15 (6): 423-33
12. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004 Sep; 44 (9): 951-65
13. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007 Nov; 86 (11): 1022-33
14. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007 Mar; 119 Suppl. 2: S150-62
15. Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008 Jun; 19 (6): 732-59
16. Delmas PD, Recker RR, Chesnut 3rd CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004 Oct; 15 (10): 792-8
17. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006 May 25; 54 (6): 1838-46
18. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008 Mar; 35 (3): 488-97
19. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005 Aug; 20 (8): 1315-22
20. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006 May; 65 (5): 654-61
21. Silverman SL, Barrett-Connor E, Simonelli C, et al. Rapid suppression of serum CTX within three days of treatment initiation with monthly oral ibandronate [abstract no. 1546]. Arthritis Rheum 2007 Sep 1; 56 Suppl. 9: 610
22. Lewiecki EM, Keaveny TM, Kopperdahl D, et al. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. Epub 2008 Oct 7
23. Recker RR, Weinstein RS, Chesnut 3rd CH, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporosis Int 2004 Mar; 15 (3): 231-7
24. Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002 Jan; 30: 320-4
25. Reginster JY, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab 2005; 90 (9): 5018-24
26. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005; 39: 668-77
27. Chesnut 3rd CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19 (8): 1241-9
28. Bachmann G, Barr CE, Gass M. Ibandronate reduces fracture rates in patients younger than 60 years with low lumbar spine bone mineral density. Obstet Gynecol 2006 Apr; 107 Suppl. 4: 82-3
29. Felsenberg D, Miller P, Armbrecht G, et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 2005 Nov; 37 (5): 651-4
30. Miller PD, Epstein S, Sedarati F, et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008 Jan; 24 (1): 207-13
31. Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol 2008 Aug; 27 (8): 955-60
32. Recknor C, Lillestol M, Grant R, et al. Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension [abstract no. W363]. J Bone Miner Res 2007; 22 Suppl. 1: 453
33. Bianchi G, Garcia-Hernandez P, Grant R, et al. The DIVA study long-term extension: maintained efficacy with quarterly intravenous ibandronate injection [abstract no. SAT0292]. 2007 Annual European Congress of Rheumatology; 2007 Jun 13-16; Barcelona
34. Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005 Mar; 21 (3): 391-401
35. Emkey R, Chesnut 3rd CH, Schimmer RC, et al. Benefits of oral ibandronate on non-vertebral fracture risk in postmenopausal osteoporosis: further analyses from a pivotal phase III study [abstract no. T389]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: S329
36. Zaidi M, Epstein S, Harris ST, et al. Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates. Ann N Y Acad Sci 2007 Nov; 1117: 273-82
37. Data on file. Roche Laboratories Inc., Nutley (NJ), 2008
38. Riis BJ, Ise J, von Stein T, et al. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001 Oct; 16 (10): 1871-8
39. Ravn P, Clemmesen B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996 Nov; 19 (5): 527-33
40. Tanko LB, McClung MR, Schimmer RC, et al. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 2003 Apr; 32: 421-6
41. Nakamura T, Mizunuma H, Itabashi A, et al. Monthly oral ibandronate is well tolerated and efficacious in Japanese osteoporotic subjects [abstract no. T405]. J Bone Miner Res 2007; 22 Suppl. 1: 333
42. Recker R, Stakkestad JA, Chesnut 3rd CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004 May; 34 (5): 890-9
43. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004 May; 34 (5): 881-9
44. Li M, Xing X, Meng X, et al. The efficacy and safety of intravenous ibandronate for Chinese primary osteoporostic women [abstract no. W323]. J Bone Miner Res 2007; 22 Suppl. 1: 443
45. Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003 Oct; 62 (10): 969-75
46. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997 Oct; 103 (4): 298-307
47. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008 Feb 5; 148 (3): 197-213
48. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008 Jan; 24 (1): 237-45
49. Cranney A, Wells G, Adachi R, et al. Non-vertebral fracture reduction with high- versus low-dose ibandronate: a meta-analysis of individual patient data [abstract no. LB0004]. Ann Rheum Dis 2007; 66 (Suppl. II): 681
50. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporosis Int. Epub 2008 Jul 29
51. Harris ST, Blumentals WA, Poston SA, et al. Fracture rates with monthly oral ibandronate and weekly bisphosphonates: the evaluation of ibandronate efficacy (VIBE) database fracture study [abstract no. 170 plus poster]. International Society for Clinical Densitometry 14th Annual Meeting; 2008 Mar 12-15; San Francisco (CA)
52. Harris ST, Blumentals WA, Poston SA, et al. Fracture risk with once-monthly oral ibandronate compared with weekly bisphosphonates: primary and sensitivity analyses from the evaluation of ibandronate efficacy (VIBE) database fracture study [abstract no. 408 plus poster]. American Society for Bone and Mineral Research 30th Annual Meeting; 2008 Sep 12-16; Montreal (QC)
53. Silverman SL, Blumentals WA, Poston SA, et al. Fracture risk in women aged 65 years or older with once-monthly oral ibandronate compared with weekly bisphosphonates: analyses from the evaluation of ibandronate efficacy (VIBE) database fracture study [abstract no. 367 plus poster]. American Society for Bone and Mineral Research 30th Annual Meeting; 2008 Sep 12-16; Montreal (QC)
54. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85 (1): 231-6
55. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87 (4): 1586-92
56. McClung MR, Bolognese MA, Sedarati F, et al. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal osteoporosis. Bone. Epub 2008 Oct 7
57. McClung M.R., Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004 Jan; 19 (1): 11-8
58. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005 Dec; 21 (12): 1895-903
59. Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 2007 Oct 22; 75 (3): 303-10
60. Derman R, Bonnick SL, Kohles J, et al. Improved satisfaction with monthly ibandronate in women previously receiving weekly bisphosphonates. Obstet Gynecol 2007 Apr 1; 109 Suppl. 4: 111-2S
61. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006 Aug; 60 (8): 896-905
62. Silverman SL, Cramer JA, Sunyecz JA, et al. Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12 month results from two retrospective databases [abstract no. W366]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: 454
63. Lewiecki EM, Babbitt AM, Piziak VK, et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008 Apr; 30 (4): 605-21
64. Emkey R, Bolognese M, Ragi-Eis S, et al. Tolerability of monthly ibandronate and weekly alendronate in women with postmenopausal osteoporosis: results from the MOTION Study [abstract no. 1545]. Arthritis Rheum 2007 Sep; 56 Suppl. 9: 610
65. Ettinger MP, Felsenberg D, Harris ST, et al. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol 2005 Oct; 32 (10): 1968-74
66. Binkley N, Martens MG, Kohles JD, et al. Tolerability of once-monthly ibandronate across different age groups of women switched from once-weekly bisphosphonates [abstract no. W352]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: 450
67. Miller PD, Ward P, Leigh C, et al. Intravenous ibandronate injections and oral ibandronate: Favorable renal tolerability profile in postmenopausal osteoporosis [abstract no. 1422]. Arthritis Rheum 2006 Sep 1; 54 Suppl. 9: 583-4
68. Papapoulous S, Thompson E, Hartl F. Ibandronate is not associated with an increased risk of atrial fibrillation: an assessment by annual cumulative exposure in pivotal trials [abstract no. SAT0333]. Ann Rheum Dis 2008; 67 Suppl. II: 538. Plus poster presented at the European League Against Rheumatism 2008 Annual Congress; 2008 Jun 11-14; Paris
69. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause: the Journal of the North American Menopause Society 2006; 13 (3): 340-67
70. National Osteoporosis Foundation. Fast facts on osteoporosis [online]. Available from URL: http://www.nof.org [Accessed 2008 Jul 30]
71. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 Apr; 19 (4): 399-428
72. Scottish Intercollegiate Guidelines Network. Management of osteoporosis: a national clinical guideline [online]. Available from URL: http://www.sign.ac. uk [Accessed 2008 Jul 30]
73. van Staa TP, Dennison EM, Leufkens HG, et al. Epidemiology of fractures in England and Wales. Bone 2001 Dec; 29 (6): 517-22
74. Miller PD. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Curr Med Res Opin 2008 Jan; 24 (1): 107-19
75. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997 Aug 18; 103 (2A): 20-5S
76. Cummings SR, Melton LJI. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-7
77. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and morbidity associated with hip fracture. Osteoporosis Int 2004 Nov; 15 (11): 897-902
78. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [online]. Available from URL: http://www.nof.org [Accessed 2008 Sep 16]
79. Sambrook PN, Seeman E, Phillips SR, et al. Preventing osteoporosis: outcomes of the Australian Fracture Prevention summit. Med J Aust 2002; 176 (8 Suppl.): 1-16
80. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE technology appraisal guidance 160 [online]. Available from URL: http://www.nice-.org.uk/guidance/TA160 [Accessed 2008 Nov 24]
81. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE technology appraisal guidance 161 [online]. Available from URL: http://www.nice.org.uk/guidance/TA161 [Accessed 2008 Nov 24]
82. Delmas PD, Siris ES. NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women. Bone 2008; 42 (1): 16-8
83. Brown JP, Josse RG. Scientific Advisory Council of the Osteoporosis Society of Canada. CMAJ 2002 Nov 12; 167 (10 Suppl.): S1-34
84. Lakatos P, Christiansen C, Marton I. New Europe: consensus on osteoporosis 2003. Developed by the 2nd Central and Eastern European Regional Osteoporosis Meeting [online]. Available from URL: http://www.iofbonehealth.org/ download/osteofound/filemanager/policy_advocacy/pdf/lacrima.pdf [Accessed 2008 Sep 16]
85. Quseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the Americal College of Physicians. Ann Intern Med 2008; 149: 404-15
86. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 [published erratum appears in Endocr Pract 2004; 10 (1): 90]. Endocr Pract 2003 Nov; 9 (6): 544-64
87. Maricic M. New and emerging treatments for osteoporosis. Curr Opin Rheumatol 2007 Jul; 19 (4): 364-9
88. Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum 2007; 37 (1): 1-12
89. Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis: optimizing efficacy in clinical practice. Clin Interv Aging 2008; 3 (2): 279-97
90. Adami S. Bisphosphonate antifracture efficacy. Bone 2007; 41 (5 Suppl. 1): S8-15
91. Grey A, Reid IR. Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag 2006 Mar; 2 (1): 77-86
92. Cotté FE, Fautrel B, De Pouvourville G. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med Decis Making. Epub 2008 Jun 19
93. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006 Apr; 119 (4 Suppl. 1): S12-7
94. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006 Apr; 119 (4 Suppl. 1): S18-24
95. Reginster JY, Felsenberg D, Cooper C, et al. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 2006; 17 (2): 159-66
96. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006 Jun; 38 (6): 922-8
97. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006 Aug; 81 (8): 1013-22
98. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 2004 Dec; 15 (12): 1003-8
99. Reginster JY. Adherence and persistence: impact on outcomes and health care resources. Bone 2006 Feb; 38 (2 Suppl. 2): S18-21
100. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005 Sep; 21 (9): 1453-60
101. Rabenda V, Mertens R, Fabri V eal, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis Int 2008 Jun; 19 (6): 811-8
102. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005 Jul; 80 (7): 856-61
103. Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis Int 2006; 17 (6): 922-8
104. Simonelli C, Burke MS. Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate. Curr Med Res Opin 2006 Jun; 22 (6): 1101-8
105. Rizzoli R, Reid DM. Ibandronate: an IV injection for the treatment for postmenopausal osteoporosis. Bone 2007; 41 (5 Suppl. 1): S24-8
106. Sambrook P. Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women. Clin Interv Aging 2007; 2 (1): 65-72
107. Lewiecki EM. Long dosing intervals in the treatment of postmenopausal osteoporosis. Curr Med ResOpin 2007; 23 (11): 2617-25
108. Emkey RD. Quarterly intravenous ibandronate for postmenopausal osteoporosis. Women's Health 2008; 4 (3): 219-28
109. Novartis Pharmaceuticals Corporation, East Hanover (NJ). Zometa® (zoledronic acid) injection concentrate for intravenous infusion. Prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com [Accessed 2008 Jul 31]
110. Novartis Pharmaceuticals Corporation, East Hanover (NJ). Reclast® (zoledronic acid) injection. Prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com [Accessed 2008 Dec 11]
111. Bobba RS, Beattie K, Parkinson B, et al. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006; 29 (12): 1133-52
112. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007; 30 (9): 755-63
113. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007 Nov-2007 31; 5 (10): 475-82
114. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008 Dec; 74 (11): 1385-93
115. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003 Oct 23; 349 (17): 1676-9
116. Novartis Europharm Ltd, Horsham, UK. Aclasta 5 mg solution for infusion. Summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2008 Aug 4]
117. Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007 Aug; 29 (8): 1548-58
118. US Food and Drug Administration. Early communication of an ongoing safety review [online]. Available from URL: http://www.fda.gov/cder/drug/early_comm/ bisphosphonates.htm [Accessed 2008 Dec 11]
119. US Food and Drug Administration. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates [online]. Available from URL: http://www.fda.gov/cder/drug/ early_comm/bisphosphonates_update_200811.htm [Accessed 2008 Dec 11]
120. Procter & Gamble Pharmaceuticals, Inc., Cincinatti (OH). Actonel® (risedronate sodium) tablets. Prescribing information [online]. Available from URL: http://www.actonel.com/global/prescribing_information.pdf [Accessed 2008 Nov 24]
121. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006 Dec; 22 (12): 2383-91
122. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118-24
123. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporosis Int 1999; 9 (5): 461-8
124. McClung MR, Geusens P, Miller PD, et al. Effect of risendronate on the risk of hip fracture in elderly women. N Engl J Med 2001 Feb 1; 344 (5): 333-40
125. Harris ST, Watts NB, Genant HK, et al. Effects of risendronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999 Oct 13; 282 (14): 1344-52
126. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med 2007 May 3; 356 (18): 1809-22
127. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007 Nov 1; 357 (18): 1799-809
128. Earnshaw SR, Graham CN, Ettinger B, et al. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis; implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin 2007; 23 (10): 2517-29
129. Earnshaw S, Lynch NO, Cowell W, et al. Ibandronate in the treatment of postmenopausal osteoporosis: a cost-effectiveness analysis in the UK [abstract no. FRI0433]. Ann Rheum Dis 2006 Jul; 65 Suppl. II: 416. Plus poster presented at the 2006 Annual European Congress of Rheumatology; 2006 Jun 21-24; Amsterdam
130. Ettinger B, Earnshaw SR, Graham CN, et al. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with ibandronate [abstract no. M361]. J Bone Miner Res 2005 Sep; 20 Suppl. 1: 398-9
131. Earnshaw SR, Beard S, Lynch NO, et al. A comparison of the cost-effectiveness of bisphosphonates using persistence data from a UK prospective RCT [abstract no. M349]. J Bone Miner Res 2006 Sep; 21 Suppl. 1: 416-7
132. Lynch NO, Earnshaw S, Graham C, et al. Ibandronate IV injection is cost-effective in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates [abstract no. SAT0325]. 2007 Annual European Congress of Rheumatology; 2007 Jun 13-16; Barcelona
133. Earnshaw SR, Graham CN, Amonkar MM, et al. Cost-effectiveness of ibandronate injection in the treatment of US women with postmenopausal osteoporosis [abstract no. 1424]. Arthritis Rheum 2006 Sep; 54 (Suppl. 9): 584
134. Amonkar MM, Cowell W, Cooper A, et al. Ibandronate versus alendronate: a cost-effectiveness analysis using PERSIST results [abstract no. 748]. Arthritis Rheum 2006 Sep; 54 Suppl. 9: 337
135. Olson M, Brereton N, Huels J, et al. Comparison of the cost-effectiveness of zoledronic acid 5mg for the management of post-menopausal osteoporosis in the UK setting [abstract no. POS8]. Value Health 2007 Nov; 10 (6): 395-6